Journal
CLINICAL SCIENCE
Volume 135, Issue 5, Pages 703-724Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20200331
Keywords
-
Categories
Funding
- NIH [T32 HL007731]
- Array/Pfizer
- Bristol Myers Squibb
- Oncosec
- Replimune
- National Institutes of Allergy and Infectious Diseases [K08AI139375]
- Roche/Genentech
- Merck
- PACT Pharma
- Prostate Cancer Foundation
Ask authors/readers for more resources
Immunotherapies have revolutionized cancer treatment by enhancing anti-cancer immunity, but they can also lead to a wide range of inflammatory side effects, with myocarditis being the most fatal. There is currently a focus on understanding the cardiovascular toxicities associated with ICIs to inform future treatments.
Immunotherapies have greatly expanded the armamentarium of cancer-directed therapies in the past decade, allowing the immune system to recognize and fight cancer. Immune checkpoint inhibitors (ICIs), in particular, have revolutionized cancer treatment and have demonstrated survival benefit in numerous types of cancer. These monoclonal antibodies increase anti-cancer immunity by blocking down-regulators of adaptive immunity, including cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1), resulting in anti-tumor activity. As ICIs increase immune system activation, they can cause a wide range of inflammatory side effects, termed immune-released adverse events. Though these toxicities can affect nearly any organ, the most fatal toxicity is myocarditis. Here, we discuss the diverse spectrum of cardiovascular toxicities associated with ICI use. In addition, we provide insight and future directions on mechanisms and treatments for immune-related adverse events (irAEs) involving the myocardium, pericardium, vasculature, and conduction system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available